Search clinical trials for: EF2001

Total 164 results

Vedic Lifesciences Pvt. Ltd.

Recruiting

A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese Adults

Gastrointestinal Dysfunction

India
ExoRNA Bioscience

Recruiting

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

Huntington Disease

China
Emmecell

Active, not recruiting

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Endothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial Decompensation

United States
Frontier Biotechnologies Inc.

Recruiting

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Mild to Moderate COVID-19

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
Frontier Biotechnologies Inc.

Completed

A Bridging Study of FB2001 in Healthy Subjects

COVID-19

China
Frontier Biotechnologies Inc.

Recruiting

Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

COVID-19

China
Frontier Biotechnologies Inc.

Completed

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

Covid19

United States
Eisai Inc.

Completed

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Chronic Plaque Psoriasis

United States
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Equillium
Biocon Limited; Equillium AUS Pty Ltd

Completed

A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma (EQUIP)

Asthma

New Zealand, Australia
Ruijin Hospital
Frontier Biotechnologies Inc.; Shanghai Center for Disease Control and Prevention

Not yet recruiting

Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts

Close Contact Transmission
National Eye Institute (NEI)

Completed

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Hippel-Lindau Disease

United States
Frontier Biotechnologies Inc.

Completed

A Study of FB2001 for Inhalation in Healthy Chinese Adults

COVID-19 Pandemic

China
SNLD, Ltd.

Active, not recruiting

Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease

Parkinson Disease

Japan
Enyo Pharma
PRA Health Sciences

Completed

Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Healthy
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Charite University, Berlin, Germany
German Federal Ministry of Education and Research; University of Potsdam; Brandenburg...

Unknown

TDCS in Acute Stroke (TDCS-aphasia)

Stroke

Germany
Equillium
Biocon Limited

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD (EQUATE)

GVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host Disease

United States
Asociación para Evitar la Ceguera en México
Emmecell

Recruiting

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Endothelial Dysfunction | Corneal Edema | Fuchs' Endothelial Dystrophy | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Edema Pseudophakic

Mexico
Eisai Inc.

Completed

A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

United States
Eisai Inc.

Terminated

A Study of E2007 In Patients With Parkinson's Disease

Parkinson's Disease

United States
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
Equillium
Biocon Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 (EQUINOX)

Coronavirus

Colombia
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

COVID-19

China
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Hangzhou Jiayin Biotech Ltd

Recruiting

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type 1

Spinal Muscular Atrophy Type I

China
Woebot Health
Iqvia Pty Ltd

Terminated

[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]

Postpartum Depression

United States
Eisai Inc.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

Elderly | Chronic Insomnia | Adults

United States
Eisai Inc.

Completed

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Migraine Prophylaxis

United States
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
University of Florida
Cord for Life, Inc.

Recruiting

Open Label Dose Ranging Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ) (SIJ)

Pain, Back | Sacroiliac; Backache

United States
Eisai Inc.

Completed

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Evolve BioSystems, Inc.
University of California, Davis

Completed

Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants (REMEDI)

Gut Microbiome

United States
Eyetech Pharmaceuticals

Completed

Phase II/III Study of Anti-VEGF in Neovascular AMD

Macular Degeneration | Choroidal Neovascularization

United States
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
ENCell

Completed

Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

Charcot-Marie-Tooth Disease, Type IA

Korea, Republic of
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Eisai Inc.

Completed

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

Metabolism and Excretion

United States
Eisai Inc.

Completed

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

Insomnia

United States
ENCell

Not yet recruiting

Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Korea, Republic of
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Tetanus

China
Epimmune

Completed

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Neoplasm

United States
Eisai Co., Ltd.

Completed

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Epilepsy

Germany
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Terminated

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Neuralgia

United States, Canada

3

Subscribe